explore -WSS

explore

author：comprehensive 2025-09-27 23:53:08 - browse：9

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Future doctors need a strong humanities education

WSS

Medicare Advantage's lean provider networks lead CMS complaints

High breast density mammograms need follow

Head of FDA's diagnostics center, who led through Covid, retires

STAT wants to know your pick for a great summer read or listen

To bolster infectious disease surveillance, genomics powerhouses team up

FDA endorses new sterilization method for medical devices

focus

explore

leisure time

Moonlake's readout produced a cash windfall. Risks remain

Dana Farber says 6 studies to be retracted and 31 corrected

Psychedelics group wrestles with new pharma identity

Head of FDA's diagnostics center, who led through Covid, retires

The high cost of giving birth even with insurance

Medicare bonuses could stop drug shortages under Senate plan

After affirmative action ruling, medical educators look to 'holistic review'

How CO2 helps viruses stay alive longer in the air

Virginia high school admissions case could be legal follow

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

focus

Flu vaccine reformulation won't be easy, manufacturers warn

Mass General, Mayo Clinic look to monetize custom

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

To bolster infectious disease surveillance, genomics powerhouses team up

FTC loses bid to block Novant's North Carolina hospital merger

FDA sets aggressive timeline for overhauling inspection procedures

leisure time

hotspot

Wikipedia

Wikipedia